Lomerizine Hydrochloride

HCID 122125CAS 101477-54-7

Teilstruktursuche Ähnliche Strukturen suchen

Grundinformationen

Standard-SMILES: COc1ccc(CN2CCN(C(c3ccc(F)cc3)c3ccc(F)cc3)CC2)c(OC)c1OC.Cl.Cl
InChIKey: LOGVKVSFYBBUAJ-UHFFFAOYSA-N
Summenformel: C27H32Cl2F2N2O3
Durchschnittliche Molmasse: 541,5 g/mol
Monoisotopische Masse: 540,1758046

Namen und Bezeichner

Bevorzugter Name: Lomerizine Hydrochloride
IUPAC: 1-[bis(4-fluorophenyl)methyl]-4-[(2,3,4-trimethoxyphenyl)methyl]piperazine;dihydrochloride
Englischer Name: Lomerizine hydrochloride
Summenformel: C27H32Cl2F2N2O3
Molmasse: 541.46

Namen und Synonyme

Lomerizine dihydrochlorideLomerizine hydrochloride1-(bis(4-fluorophenyl)methyl)-4-(2,3,4-trimethoxybenzyl)piperazine dihydrochlorideDTXSID10464273W473D5LIY1-[BIS(4-FLUOROPHENYL)METHYL]-4-(2,3,4-TRIMETHOXYBENZYL)PIPERAZINE DIHYDROCHLORIDE1-(Bis(4-fluorophenyl)methyl)-4-((2,3,4-trimethoxyphenyl)methyl)piperazine dihydrochloride1-[bis(4-fluorophenyl)methyl]-4-[(2,3,4-trimethoxyphenyl)methyl]piperazine dihydrochlorideDTXCID9026427RefChem:153988686-037-9101477-54-7

Weitere Namen anzeigen

Flometizine hydrochlorideKB 2796TERRANASLomeizine HCLLomerizine2HClLOMERIZINE DIHCLKB-2796, TerranasKB-2796 dihydrochlorideLOMERIZINEHYDROCHLORTDE

Lomerizine HClKB-2796MFCD017038671-(2,3,4-Trimethoxybenzyl)-4-(bis(4-fluorophenyl)methyl)piperazine dihydrochloride1-[bis(4-fluorophenyl)methyl]-4-[(2,3,4-trimethoxyphenyl)methyl]piperazine;dihydrochloridePiperazine, 1-[bis(4-fluorophenyl)methyl]-4-[(2,3,4-trimethoxyphenyl)methyl]-, hydrochloride (1:2)Lomerizine hydrochloride (JAN)LOMERIZINE 2HCL

Datenbank-Bezeichner

CAS: 101477-54-7
PubChem CID: 122125
DTXSID: DTXSID1046427
ChEMBL: CHEMBL2356978
UNII: 3W473D5LIY
EC Number: 686-037-9

Eigenschaften

Berechnete Struktureigenschaften

Polarare Oberfläche (TPSA): 34,2 Å²
H-Brücken-Donoren: 2
H-Brücken-Akzeptoren: 7
Frei drehbare Bindungen: 8
Schwere Atome: 36
Formalladung: 0
Komplexität: 568

Physikochemische Eigenschaften

Schmelzpunkt: 214 · 214-218°C dec.
storage temp.: 2 · Inert atmosphere,2-8°C
Löslichkeit: 30 mg/mL · DMSO: ≥30mg/mL
Aggregatzustand: powder
Farbe: white to tan
Merck: 14 · 14,5563
Stabilität: 1 year · Stable for 1 year from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20°C for up to 1 month.
InChIKey: LOGVKVSFYBBUAJ-UHFFFAOYSA-N
SMILES: C(C1C=CC(F)=CC=1)(C1C=CC(F)=CC=1)N1CCN(CC2C=CC(OC)=C(OC)C=2OC)CC1.Cl.Cl
CAS Datenbank: 101477 · 101477-54-7(CAS DataBase Reference)

Sicherheit und Regulatorisches

GHS-Klassifizierung

GHS Classification · 5 Einträge

Warning

H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]；H400 (97.5%): Very toxic to aquatic life [Warning Hazardous to the aquatic environment, acute hazard]；H410 (97.5%): Very toxic to aquatic life with long lasting effects [Warning Hazardous to the aquatic environment, long-term hazard]

P264, P270, P273, P301+P317, P330, P391, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 40 reports by companies from 2 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.；Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. For more detailed information, please visit ECHA C&L website.

Gefahrenhinweise

Hazard Classes and CategoriesAcute Tox. 4 (100%)；Aquatic Acute 1 (97.5%)；Aquatic Chronic 1 (97.5%)

Sicherheitsdaten

wgk: 3
ridadr: UN 3077 9 / PGIII
hs_code: 29335990
RTECS-Nr.: TK9189000
risk_code: 22-50
Toxizität: LD50 orally in mice: 300 mg/kg (Ohtaka)
hazard_code: Xn,N
safety_code: 61

Chemie und Industrie

Pharmakologische Informationen

MeSH Pharmacological ClassificationA class of drugs that act by selective inhibition of calcium influx through cellular membranes.

Anwendungen · 2 Einträge

BeschreibungLomerizine hydrochloride was introduced as Teranas and Migsis in Japan for the treatment of migraine. It is the first in its class of dual sodium and calcium channel blockers to be marketed for this indication. It can be synthetically obtained by reductive amination of 2,3,4-trimethoxybenzaldehyde with the appropiate benzhydryl piperazine. In dogs, Lomerizine exerts a potent, selective and long-lasting vasodilation of cerebral arteries related to a combination of mechanisms, especially a functional block of L-type voltagesensitive calcium channels (L-VSCCs). Lomerizine increases cerebral blood flow compared to peripheral blood flow with only weak effects on systemic arterial blood pressure. Other mechanisms involved could be blockade of other VSCC and sodium channels, 5-HT2 and alpha-1 receptors. As a reducing agent of cortical spreading depression and neurogenic inflammation, Lomerizine was shown to be useful in migraine. In an open clinical study, it demonstrated efficacy in the treatment of cluster headache. Moreover, it may have utility in other neurological diseases such as cerebrovascular ischemia or cerebral infarction.

VerwendenA diphenylpiperazine calcium channel blocker. A selective cerebral vasodilator. Antimigraine.